Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash & Current Investments (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Cash & Current Investments over the past 16 years, most recently at $8.3 million for Q2 2025.

  • For Q2 2025, Cash & Current Investments fell 2.33% year-over-year to $8.3 million; the TTM value through May 2025 reached $8.3 million, down 2.33%, while the annual FY2025 figure was $8.3 million, 2.33% down from the prior year.
  • Cash & Current Investments for Q2 2025 was $8.3 million at Lifecore Biomedical, Inc. \De\, up from $5.4 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $19.1 million in Q2 2023 and troughed at $609000.0 in Q4 2021.
  • A 5-year average of $4.9 million and a median of $2.7 million in 2022 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: crashed 75.4% in 2021 and later soared 1826.44% in 2023.
  • Year by year, Cash & Current Investments stood at $609000.0 in 2021, then skyrocketed by 875.04% to $5.9 million in 2022, then surged by 221.51% to $19.1 million in 2023, then crashed by 50.47% to $9.5 million in 2024, then dropped by 12.59% to $8.3 million in 2025.
  • Business Quant data shows Cash & Current Investments for LFCR at $8.3 million in Q2 2025, $5.4 million in Q1 2025, and $9.5 million in Q4 2024.